Practical Use of Upadacitinib in Patients with Severe Atopic Dermatitis in a Real-World Setting: A Systematic Review

• Published in: Clinical, cosmetic and investigational dermatology cosmetic and investigational dermatology, 2024-01, Vol.17, p.593-604
• Main Authors: Ibba, Luciano, Gargiulo, Luigi, Vignoli, Carlo Alberto, Fiorillo, Giovanni, Valenti, Mario, Costanzo, Antonio, Narcisi, Alessandra
• Format: Article
• Language: English
• Subjects: Advertising executives; Atopic dermatitis; Care and treatment; jaki; Pharmaceutical industry; real-life; systematic review; upadacitinib
• ISSN: 1178-7015; 1178-7015
• DOI: 10.2147/CCID.S329442

Upadacitinib is a selective Janus kinase inhibitor approved for the treatment of severe atopic dermatitis (AD). This systematic review aims to summarize the most recent data in terms of effectiveness and safety of upadacitinib in the treatment of severe AD in a real-world setting. The review included a comprehensive search of databases, including PubMed, Google Scholar and Web of Science, according to Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA) guidelines. The literature search initially identified 242 studies. Of these, 214 were excluded after reviewing their titles and abstracts. We then conducted a full-text review of 25 studies, of which 17 met our inclusion criteria and were therefore included in our systematic review. The analysis of real-world studies showed high effectiveness of upadacitinib, in terms of both clinical signs and subjective symptoms, in different patient populations, including those resistant to other treatments. No new significant safety concerns have emerged as compared to randomized clinical trials.